How Many Akorn, Inc. (NASDAQ:AKRX)’s Analysts Are Bearish?

September 16, 2018 - By Brian Ramirez

Akorn, Inc. (NASDAQ:AKRX) Ratings Coverage

Among 3 analysts covering Akorn (NASDAQ:AKRX), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Akorn had 3 analyst reports since March 29, 2018 according to SRatingsIntel. The rating was maintained by Craig Hallum on Monday, April 23 with “Hold”. The stock has “Hold” rating by RBC Capital Markets on Thursday, March 29. The rating was maintained by Piper Jaffray with “Hold” on Monday, April 23. Below is a list of Akorn, Inc. (NASDAQ:AKRX) latest ratings and price target changes.

23/04/2018 Broker: Craig Hallum Rating: Hold New Target: $14.0000 Maintain
23/04/2018 Broker: Piper Jaffray Rating: Hold Maintain
29/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $25.0000 Maintain

The stock increased 1.03% or $0.14 during the last trading session, reaching $13.73. About 1.16M shares traded. Akorn, Inc. (NASDAQ:AKRX) has declined 57.63% since September 16, 2017 and is downtrending. It has underperformed by 73.25% the S&P500.

Akorn, Inc., a specialty generic pharmaceutical company, develops, makes, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the United States and internationally. The company has market cap of $1.72 billion. The firm operates in two divisions, Prescription Pharmaceuticals and Consumer Health. It currently has negative earnings. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics.

More news for Akorn, Inc. (NASDAQ:AKRX) were recently published by:, which released: “Nostrum Labs hikes price of mature antibiotic 400%” on September 12, 2018.‘s article titled: “AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?” and published on August 27, 2018 is yet another important article.

Akorn, Inc. (NASDAQ:AKRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.